Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year.

Robert F. Kennedy Jr., who awaits confirmation as Donald Trump's Health and Human Services secretary, helped organize mass ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Chevron Corporation (c), Merck & Co., ...

Magnificent Seven stocks. Big Tech's runaway growth created gains, but headwinds are forming and some observers doubt the Mag ...

Monday, three Big Pharma leaders took center stage and addressed concerns about future patent expirations head-on.

Analyst Daina Graybosch of Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research Report), reducing the price target ...

Organon has faced significant price volatility and underperformance since its spin-off from Merck. Check out why I recommend ...

Key Takeaways Merck faces headwinds like declining sales of the HPV vaccine, Gardasil, and diabetes drug, Januvia. Merck ...

BMO Capital analyst Evan Seigerman has maintained their neutral stance on MRK stock, giving a Hold rating on January 10.Stay Ahead of the ...

JPM25 is in full swing as several pharma powerhouses—including Merck, Lilly and Amgen—detail their strategies for growth in ...